Sponsor or institution

Clinical trials and research at Fondazione Ricerca Traslazionale

• 5Clinical trials
• 1Country

Newest trials

All recruiting trials (5)

• Amivantamab plus single‑agent chemotherapy for advanced non‑small cell lung cancer with EGFR exon 20 insertion in people unable to receive platinum

  This trial will test whether adding amivantamab to a single chemotherapy drug helps people with metastatic non‑small cell lung cancer that has an EGFR exon 20 insertion who cannot get platinum chemotherapy.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, Roma (RM) · NCT07392658

• Cemiplimab plus TEDOPI maintenance for ctDNA‑positive HLA‑A2 advanced NSCLC

  This trial will test whether adding the TEDOPI vaccine to cemiplimab as maintenance can clear circulating tumor DNA in HLA‑A2 positive advanced NSCLC patients who did not progress after four cycles of chemo‑immunotherapy.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, RM · NCT07264673

• Neoadjuvant chemo-immunotherapy for PD-L1–positive Stage III non-small cell lung cancer

  This tests whether three cycles of combined chemotherapy and the immunotherapy drug tislelizumab given before local treatment help adults with Stage III PD-L1–positive non-small cell lung cancer who are past or current smokers and do not have EGFR/ALK/ROS1/RET driver alterations.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Rome, Roma (RM) · NCT07264647

• Investigating immune responses in lung cancer patients receiving immunotherapy

  This study looks at how the immune system responds in lung cancer patients receiving immunotherapy to see if these responses affect how well the treatment works and any side effects they might have.

  Recruiting Fondazione Ricerca Traslazionale · Roma, RM and 1 other locations · NCT06823401

• Comparing standard chemotherapy with immune-based combinations for relapsed stage III non-small-cell lung cancer after chemoradiotherapy and durvalumab

  This study tests whether adding durvalumab to second-line single-agent chemotherapy, or adding olaparib to durvalumab, helps people with stage III non-small-cell lung cancer who relapse after chemoradiotherapy and durvalumab live longer.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, RM · NCT05568212

Quick answers

How many clinical trials run by Fondazione Ricerca Traslazionale are recruiting right now?

5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in Italy. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →